Skip to main content
. 2017 Nov 27;8(65):109596–109608. doi: 10.18632/oncotarget.22741

Figure 6. TRIB2 and CEBPA proteins in SCLC patients.

Figure 6

(A) Patient 1: CT scan before and two months after Cisplatin treatment. (B) Patient 2: CT scan before and two months after Cisplatin treatment. (Arrows indicate tumor.) (C) Tumor sample from the Cisplatin-sensitive Patient 1 did not express TRIB2 protein. (D) Tumor sample from the Cisplatin-resistant Patient 2 presented high levels of TRIB protein in the cytoplasm and nucleus of tumor cells. (E) Tumor sample from Patient 1 demonstrated CEBPA protein in the nucleus of the tumor cells. (F) Tumor sample from the Patient 2 did not have detectable CEBPA protein levels.